Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Fifth Avenue Growth Fund Alex Umansky | “Intuitive Surgical, Inc. sells robotic-assisted surgical systems. Shares declined 13.7% after the company's first-quarter U.S. system placements came in below investor expectations. Medical device stocks also broadly underperformed the market amid concerns that health care utilization trends could decelerate following the expiration of Affordable Care Act subsidies. Concerns were further compounded by the potential impact of Medicaid work requirements expected to take effect in 2027. Despite these headwinds, which we view as short-term in nature, we believe Intuitive can continue to grow revenue at a mid-teens rate for many years and remain positive on the company's long-term growth outlook.” | BEAR | Q2 2026 Aug 14, 2026 | View Pitch |
Sands Capital Global Growth Fund Brian A. Christiansen, David E. Levanson, Daniel Pilling | “Intuitive Surgical is a leading provider of robotic surgical systems. Shares came under pressure with the broader medtech industry. Health care equipment and supplies was among the weakest industries in the quarter, as investors weighed fewer product cycles, health care utilization concerns, inflation, competition for capital from AI infrastructure, and concerns about ex-U.S. competition. We believe the share price pressure obscures a stronger fundamental setup. First-quarter 2026 results beat consensus estimates across key metrics, including revenue, non-GAAP earnings, non-GAAP operating margins, da Vinci procedures, and overall robot placements. Looking ahead, we expect Intuitive to roll out several AI features over the next few years, including anatomy identification, critical-structure highlighting during surgery, and, over time, support for surgeon dexterity and automation. These features could accelerate robotic surgery adoption and create a software licensing opportunity that we expect to carry higher gross margins than the corporate average. While we do not expect a quick rerating in the shares, which trade at levels not seen since the 2022 market selloff, we favor the risk/reward profile given Intuitive's recurring revenue base, market leadership, and longer-term AI potential.” | NEUTRAL | Q2 2026 Jul 31, 2026 | View Pitch |
Edgewood Management Alan Breed | “Intuitive Surgical showed 38% year-over-year EPS growth in the most recent quarter. Portfolio weighting is 4.4% as of June 30, 2026. Edgewood estimates 2026 EPS of $9.87 (40x P/E) and 2027 EPS of $12.12 (33x P/E), representing 22% growth in 2025-2026 and 23% growth in 2026-2027, with a 5-year estimated growth rate of 20%. Intuitive Surgical repurchased $1.1B in Q1 2026 and raised buyback authorization to $5B. The portfolio added 1.0% to Intuitive Surgical position during Q2 2026. Intuitive Surgical is spearheading robotics' entry into healthcare.” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
TCW Concentrated Large Cap Growth Fund Brandon D. Bond, Bo Fifer, Brian M. McNamara | “Shares of Intuitive Surgical, Inc. (ISRG; 1.93%) moved lower despite releasing solid quarterly results. Revenue and Da Vinci procedure growth topped consensus estimates, but China and Japan system placements continue to disappoint, however. ISRG repurchased 2.3M shares of its common stock (for $1.1B) in 1Q26 and management raised 2026 guidance. Shares have been challenged YTD due to increasing negative investor sentiment in health care medtech stocks, as well as the fact that ISRG is a high-growth, high multiple security. We note that we are still relatively early in the launch of Da Vinci 5, which we believe will drive further penetration (both into new hospitals and into new procedure categories) and further establish ISRG's lead in robotic-assisted surgery. ISRG has a 20-year lead on competitors, a strong competitive moat, and we remain constructive on shares.” | NEUTRAL | Q2 2026 Jul 29, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Intuitive Surgical, Inc. sells robotic-assisted surgical systems. Shares declined after the company's first-quarter U.S. system placements came in below investor expectations. Medical device stocks also broadly underperformed the market amid concerns that health care utilization trends could decelerate following the expiration of Affordable Care Act (ACA) subsidies. Concerns were further compounded by the potential impact of Medicaid work requirements expected to take effect in 2027. Despite these headwinds, we believe Intuitive can continue to grow revenue at a mid-teens rate for many years and remain positive on the company's long-term growth outlook.” | BEAR | Q2 2026 Jul 23, 2026 | View Pitch |
Ithaka US Growth Strategy Scott O'Gorman, Andy Colyer, Daniel White | “Intuitive Surgical is a pioneering medical technology company best known for its da Vinci robotic surgical system, which enables surgeons to perform precise, minimally invasive procedures. The system is widely used in urologic, gynecologic, general, and hernia repair surgeries, offering patients reduced pain, blood loss, and recovery time compared to traditional approaches. Intuitive generates revenue through three primary streams: system sales, instruments and accessories (such as scalpels, graspers, and cauterization tools), and services, which includes maintenance, training, and technical support, creating a high-margin recurring revenue model anchored by a growing global installed base of 10,200 units. The stock's second quarter underperformance was due to multiple contraction, which dinged the stock for 21%, slightly offset by strong forward earnings growth. The multiple compression was largely due to the AI narrative 'sucking all the oxygen out of the room.'” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
The Heptagon Future Trends Fund Portfolio Manager | “As the pioneer of minimally invasive robotic surgery, Intuitive Surgical boasts a massive global installed base and an highly compelling razor-and-blade business model. Over 80% of its revenues are recurring and derived from high-margin consumables, with additional upside from its strategic shift toward software solutions.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Ithaka US Growth Strategy Scott O'Gorman, Andy Colyer, Daniel White | “Intuitive Surgical is a pioneering medical technology company best known for its da Vinci robotic surgical system, which enables surgeons to perform precise, minimally invasive procedures. The system is widely used in urologic, gynecologic, general, and hernia repair surgeries, offering patients reduced pain, blood loss, and recovery time compared to traditional approaches. Intuitive generates revenue through system sales, instruments and accessories, and services such as maintenance, training, and technical support, creating a high-margin recurring revenue model anchored by a growing global installed base of over 10,200 units. The stock's fourth quarter outperformance was concentrated in a single day in which the company posted a massive earnings beat, besting consensus by approximately 5% on the top line and 20% on the bottom line. This beat sent the stock up 14%, with momentum carrying through to the end of the quarter. BSD Analysis: Intuitive Surgical owns robotic surgery mindshare in a way competitors still haven't meaningfully cracked. The installed base creates a razor-and-blade model through instruments, services, and recurring utilization. Hospitals don't switch platforms casually because training and workflow risk are enormous. Procedure expansion across specialties continues to widen the moat. Capital spending cycles add noise, not structural risk. Investors obsess over valuation because dominance looks expensive. Innovation cadence keeps reinforcing leadership. Margins reflect ecosystem control, not device sales alone. This is surgical infrastructure, not a medtech fad.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Brown Advisory Large-Cap Growth Strategy Brown Advisory LLC | “Intuitive Surgical delivered strong quarterly results that eased concerns around hospital spending and procedure growth. Procedure volumes rose 19% year-over-year, well ahead of consensus expectations, and system placements exceeded forecasts. Growth was driven by robust adoption of the Da Vinci 5 platform across multiple geographies. These results underscored Intuitive's leadership in robotic surgery and its ability to sustain long-term growth. The company continues to deepen its installed base and recurring instrument revenue. BSD Analysis: Intuitive's moat is an ecosystem—hardware, software, instruments, and surgeon training locked together. Once a hospital commits to da Vinci, switching is operationally and politically painful. Recurring instrument revenue drives margins far more than system sales. Procedure growth is steady, not explosive, but incredibly durable. Competition exists, yet adoption curves favor the incumbent with the deepest installed base. Pricing power is subtle and realized over time through utilization, not sticker price. The bull case is continued procedural expansion and platform extensions. The bear case is slower adoption or reimbursement friction. Intuitive compounds by owning surgical workflows, not by chasing unit growth.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Edgewood Management Alan Breed | “The company's leading position in robotic-assisted surgery continues to support durable high-teens revenue growth and strong earnings compounding. The manager views a recent post-earnings selloff as an unwarranted macro-driven decline, representing an attractive opportunity to increase position size given the company's robust moat and deep addressable market.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Edgewood Management Alan Breed | “Global leader in robotic-assisted surgical systems, instruments and accessories with its da Vinci and Ion endoluminal platforms. Thesis: ISRG benefits from a large installed base, expanding recurring revenue from instruments, accessories and service, and the growing secular adoption of robotics in surgical applications. Q2 Results: Revenue +21% and EPS +23%. Procedure volumes +17%; raised FY25 GM guidance. Total placements of 395 units missed consensus by one. What Happened: Stock traded down 2% post-earnings and throughout the quarter alongside the broader Healthcare/MedTech market. Edgewood's View: We viewed the broader MedTech selloff as unwarranted. Following diligence in several areas, we felt confident in ISRG's competitive moat and long-term addressable market opportunity. We believe ISRG can compound revenue in the high teens and EPS 20+%. Resulting Action: Edgewood added 100bps to its position in September. BSD Analysis: Intuitive Surgical has effectively transitioned into 2026 as a global diversified leader in robotic-assisted surgery, with international procedure volumes now outpacing domestic U.S. growth. The company reported a significant 35% surge in international procedures in late 2025, particularly in Europe and Asia, which is helping to de-risk its revenue profile from domestic regulatory shifts. Management expects 2026 organic sales growth to settle between 6.5% and 7.5%, driven by the continued rollout of the Da Vinci 5 platform and its expansion into diagnostic lung procedures with the Ion system. While the stock trades at a premium forward P/E of approximately 49, this valuation remains below its five-year median, reflecting a more mature but highly profitable business model. With a 12.3% projected rise in annual earnings, Intuitive remains the gold standard in medtech, benefiting from a high percentage of recurring revenue through instruments and accessories.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Baron Fifth Avenue Growth Fund Alex Umansky | “Intuitive Surgical, Inc. manufactures the da Vinci robotic surgical system for minimally invasive surgical procedures. Shares detracted from performance in the quarter declining 17.7%, due to system placements in the U.S. falling short of investor expectations. In addition, investors are concerned about financial pressure on hospital customers resulting from cuts to Medicaid in the One Big Beautiful Bill Act. Finally, concerns emerged about the use of reprocessed instruments from third parties with Intuitive's robotic systems. We believe it is unlikely that hospitals would be willing to take a risk using third party reprocessed instruments because of the potential for quality, reliability, and liability issues. We continue to believe Intuitive has a long runway for growth driven by the continued adoption of the company's robotic systems in an expanding number of surgical procedures. BSD Analysis: Intuitive is the definition of medical device compounding: razor/razorblade economics with recurring revenue and deep clinical switching costs. Once a hospital commits to da Vinci, the ecosystem locks in through training, workflow, and consumables. Growth is steady, not explosive, which is why the stock lives or dies by valuation discipline. Competitive threats exist, but adoption curves in surgery move at glacial speed—favoring incumbents. The risk is procedure volumes in downturns and pricing pressure from cost-conscious hospitals. Still, this is one of the rare medtech franchises with true platform characteristics. It's expensive because it deserves to be.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Tall Oak Capital Advisors Shawn Jakupi, Mehendi Kamani | “Intuitive Surgical continues to be a prime beneficiary of the shift toward minimally invasive care — a preference that's particularly pronounced among aging patients and hospitals managing resource constraints. The company's Da Vinci robotic surgery systems are now deployed across thousands of hospitals globally, and Q2 2025 marked a record-setting quarter: 110 new placements, up from 70 the previous quarter. What drives this growth? In short: real-world demand. Hospitals increasingly prefer robotic-assisted procedures for their shorter recovery times, reduced infection risks, and greater surgical precision — all critical factors in aging populations undergoing hernia repair, prostatectomy, or cardiac surgery. Why we like it: • High-margin, recurring revenue from service contracts and surgical instruments • Strong balance sheet with no debt and a long runway for global adoption • A “pick-and-shovel” approach to rising surgical volumes in aging populations. As AI spreads into physical healthcare applications, Intuitive is well positioned at the intersection of automation, medicine, and demographic necessity. BSD Analysis: Intuitive Surgical is the undisputed, monopolistic king of robotic surgery whose stock is a conviction bet on the long-term, non-cyclical adoption of its da Vinci system. The core moat is its classic "razor-and-blade" business model: the massive installed base of da Vinci systems (the "razor") drives a massive, recurring, and high-margin revenue stream from proprietary instruments and accessories (the "blades"). The company continues to widen its technological gap with the launch of the da Vinci 5, which features 10,000x the computing power of its predecessor. This is an indispensable MedTech compounder, leveraging three decades of experience and 14 million procedures performed to secure its long-term dominance.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
